More than 18 months ago, federal officials recalled Belviq’s cancer risks connected with the diet drug’s use. However, as new instances of Belviq illness continue to surface, and patients realize that Belviq’s side effects may have caused successfully treated cancer, the number of cases filed worldwide continues to rise.
The attorneys represent individuals who have been diagnosed with this cancer.
- Cancer of the pancreas
- cancer of the colon
- Cancer of the Lung
- Women’s Health Issues
- Some Belviq-Induced Cancers
These instances will continue to surface for many years. It is estimated that more than 1,000 people will be eligible for a Belviq settlement in the future because of the lengthy latency period between exposure and cancer development.
Table of Contents
What is Belviq?
A BMI of 30 or higher (obesity) or a BMI of 27 or larger (overweight) and at least any weight-related ailment such as hypertension, prediabetes, or high cholesterol were the criteria for approval of Belviq diet tablets. Three clinical studies involving less than 8,000 overweight people were the basis for the approval. Between 52 and 104 weeks, patients took medicine. Patients receiving Belviq for up to a year lost an average of 3% to 3.7 % of their body weight compared to a placebo.
The active element in Belviq is lorcaserin, which binds to the dopamine 2C receptor inside the brain and causes it to release. If this activation helps a person feel full and satisfied with smaller quantities of food, they are expected to consume less overall.
Fenfluramine, the ‘fen’ in the renowned 1990s diet pill cocktail fen-phen, targets serotonin 2C, the same appetite-controlling hormone targeted by fenfluramine. After only 18 months on the market, Fen-phen was taken off because it was connected to heart valve issues in up to one in three individuals.
Types of Cancer That May be Caused by Belviq
There is currently no information regarding the exact forms of cancers Belviq causes past users of the recalled diet pill to get from the drug developers Eisai Inc. or Arena Pharmaceuticals. If you or a loved one has been afflicted with any sort of malignant tumor, cancer is currently evaluating possible claims for compensation.
Individuals who match the following criteria are being considered for possible claims:
- Received medication and Belviq XR for weight reduction purposes;
- The FDA recalled it after at least one month of use;
- Colon Cancer, Lung Cancer, and Pancreatic Cancer.
- If It causes Cancer or other Cancer.
There may be a significant period between the last contact to Belviq and cancer diagnosis in many of these cases. Because of this, new instances are predicted to continue popping up for some time.
Working of Belvia
This medication, whose name is Belviq, works by reducing hunger. The medicine stimulates the brain’s serotonin receptors. Feelings of contentment, fulfillment, and fullness are all associated with the neurotransmitter serotonin.
Some serotonin receptors are targeted by antidepressants known as SSRIs. Belviq solely focuses on the ones that have an impact on hunger.
Regular Belviq pills may be taken twice a day by patients. Only once a day are extended-release tablets administered. People taking Belviq and following a low-calorie diet for the first 12 weeks are expected to lose 5 percent of their body mass. The medication should be discontinued if this quantity of weight reduction is not reached.
Recommendations Issued by The FDA
After lengthy safety studies found that the patients attempting to take Belviq had a higher incidence of cancers, including pancreatic, colon cancer, and lung cancer, compared with people taking a placebo, the FDA advises that stop taking it and talk to one‘s doctor regarding alternative losing weight treatments and programs.
Patients who have used Belviq diet tablets are not recommended to undergo further screening by the Food and Drug Administration. Even if a person has previously had Belviq therapy, they should still be subjected to the same cancer screening guidelines as everyone else.